

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Charles Muserlian on March 12, 2010.

Specification:

The Abstract has been amended as follows: see Page 5 of the instant amendment.

The application has been amended as follows:

Claims:

Claim **36** has been rewritten as follows: --

A method of controlling uterine mobility in women comprising administering to women in need thereof an amount of a compound of claim 14 sufficient to control uterine mobility.

--

Claim **40** has been rewritten as follows: --

A method of hormone replacement in menopausal women comprising administering to

Art Unit: 1628

menopausal women in need thereof an amount of a compound of Claim 14 sufficient for hormone replacement.

--

Claim **41** has been rewritten as follows: --

A method of treating arterial hypertension in women comprising administering to women in need thereof an amount of a compound of claim 14 sufficient to treat arterial hypertension.

--

Claim **42** has been rewritten as follows: --

A method of inducing an endometrial cycle in assisted reproduction in women comprising administering to women in need thereof an amount of a compound of claim 4-3 14 sufficient to induce an endometrial cycle.

--

Telephone Inquiry

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara P. Badio whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax

Art Unit: 1628

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Barbara P. Badio/
Primary Examiner, Art Unit 1628

Art Unit: 1628

--

Abstract

The invention concerns compounds capable of being fixed on hormone receptors and having a nitrogen monoxide donor group and their use for preventing premature births, increasing cervical dilatation, for use in hormone substitution therapy as anti-hypertensive drug and their therapeutic use for preparing a medicine for use in obstetrics and gynecology.

--